Topic: Fabry Nephropathy: Unraveling Renal Pathogenesis and Evolving Therapeutic Strategies

Fabry nephropathy, a critical aspect of Fabry disease, involves complex renal damage due to the accumulation of globotriaosylceramide (Gb3). This condition leads to progressive kidney dysfunction and, if untreated, end-stage renal disease (ESRD). Understanding the renal pathogenesis through advanced imaging, biomarkers, and genetic profiling is crucial for early intervention.

Traditional enzyme replacement therapy (ERT) has been the primary treatment, but it has limitations, including the development of antibodies and incomplete efficacy. Newer therapies, such as chaperone therapy, substrate reduction, and gene therapy, offer promising alternatives for more effective management.

This Special Issue aims to present the latest research on Fabry nephropathy, including insights into disease mechanisms, emerging biomarkers, and innovative treatments. By bringing together expert contributions, we hope to enhance the understanding and care of patients with this challenging condition.

29 Nov 2024